Recursion Pharmaceuticals Inc Clas (RXRX)
EBITDA
-$112.53M
Quarterly · Period ending: · USD
RXRX EBITDA
Latest reported-$112.53Mperiod ending
Latest reported-$112.53Mperiod ending
RXRX Quarterly EBITDA (-$17.19M → -$112.53M)
Quarterly EBITDA
High-resolution chart · PNG
RXRX ebitda history
Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA (USD) |
|---|---|
| -112,530,000 | |
| -102,085,000 | |
| -88,624,000 | |
| -141,207,000 | |
| -147,568,000 | |
| -182,806,000 | |
| -165,343,000 | |
| -87,924,000 | |
| -88,701,000 | |
| -84,755,000 | |
| -89,479,000 | |
| -85,414,000 | |
| -71,158,000 | |
| -61,580,000 | |
| -54,265,000 | |
| -57,443,000 | |
| -62,760,000 | |
| -53,198,000 | |
| -62,716,000 | |
| -44,772,000 | |
| -38,569,000 | |
| -29,066,000 | |
| -23,911,000 | |
| -22,615,000 | |
| -17,493,000 | |
| -17,186,000 |